Mayo Clinic Platform_Accelerate Announces Fourth Health Tech Cohort

Mayo Clinic Platform_Accelerate has announced its fourth cohort of health tech startups to participate in the program, which is designed to support the validation and clinical readiness of each company’s artificial intelligence (AI) solutions.

The 20-week program leverages the Mayo Clinic Platform data network to help cohort members develop their tools in accordance with healthcare industry standards. Participants also have access to clinical, technological, regulatory, and business expertise from Mayo Clinic.

The program also aims to provide resources to startups in the cohort, allowing them to further advance their business plans. As part of the arrangement, Mayo Clinic Platform maintains an equity position in each of the companies.

Mayo Clinic Platform_Accelerate's fourth cohort is made up of nine startups:

• London-based C the Signs, founded in 2017, has built a cancer prediction system to support early detection. The tool is designed to flag which types of cancer a patient may be at increased risk of and suggest the most appropriate next steps.
• Headquartered in Cambridge, Massachusetts, Genomate Health Inc.’s work is focused on the development of AI-powered computational technologies for personalized medicine. In particular, the startup’s tools are designed to provide personalized treatment decision support for clinicians.
• ISHI Health, founded last year in San Diego, California, is a virtual care solutions company specializing in heart failure care. The startup offers disease profiling and cardiac sensor technologies, in addition to other tools and services.
• Houston, Texas-based LUMINARE aims to improve sepsis outcomes and eliminate sepsis deaths. The company’s software is designed to accelerate the identification of infections and accelerate the implementation of sepsis protocols, but under the collaboration with Mayo Clinic Platform_Accelerate, the startup plans to add deep learning (DL) capabilities to address sepsis alert fatigue.
• Founded in 2021, Miami, Florida-based Alvee is a software development company focused on social determinants of health (SDOH) and health equity. The startup’s solution leverages predictive analytics to identify care barriers and help providers and payers tackle health disparities.
• DeepMetrics is an AI-driven ICU automation platform company that was founded in 2020. The company’s AI tool was developed to automatically adjust and optimize ventilator settings, and DeepMetrics is currently working to secure a 510(k) clearance from the Food and Drug Administration for the solution.
• AI Nexus, headquartered in Champaign, Illinois, aims to “democratize healthcare,” through its smartphone-based platform, miaVitals. The tool uses machine learning (ML) to detect early warning signs at the onset of numerous conditions, such as cardiac arrhythmia and stroke.
• ArtiMed specializes in developing AI-based risk stratification software-as-a-service (SaaS) tools to help payers manage long COVID and post-COVID within their populations. The company also offers solutions for pharmaceutical companies looking to identify those who may benefit from drugs for these conditions.
• Belfast, Northern Ireland-based medical technology company PulseAI develops AI software to improve cardiac diagnostics. The company’s cloud-based platform is designed to bolster the integration and deployment of AI-powered electrocardiogram (ECG) interpretation algorithms.

"We are thrilled to welcome the new cohort of Mayo Clinic Platform_Accelerate," said Jamie Sundsbak, partner relationship manager with Mayo Clinic Platform, in the press release. "These companies are at the forefront of healthcare innovation, and we are excited to work with them to accelerate their groundbreaking solutions. Together, we can make a real difference in the lives of patients around the world."